Incyte Corporation (incy)
INCY — Company Overview
Incyte Corporation (INCY) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | INCY |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $25.26B |
| Last price | $124.64 |
| Size category | Large Cap |
INCY — Business Description
INCY represents a Biotechnology business in the Healthcare segment. Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of…
Official website: https://www.incyte.com.
INCY — Investment Thesis
At a high level, INCY offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 37.7% year-over-year (public data).
- Trailing P/E of 16.17× sits in a moderate band relative to high-growth peers.
- Forward P/E (14.03×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $25.26B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
INCY — Financial Health
Key financial health indicators for Incyte Corporation are derived exclusively from public data — no proprietary estimates.
Profit margin of 27.7% indicates solid bottom-line conversion. Positive free cash flow of $1.18B supports balance-sheet flexibility.
| Trailing P/E | 16.17× |
| Forward P/E | 14.03× |
| Price / Sales | 4.34× |
| Price / Book | 3.95× |
| Gross margin | 55.7% |
| Operating margin | 41.9% |
| Profit margin | 27.7% |
| Return on equity | 30.7% |
| Debt / Equity | 0.60 |
| Free cash flow | $1.18B |
INCY — Growth Outlook
Growth outlook for Incyte Corporation (INCY) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 37.7% indicates strong top-line momentum.
- Earnings growth of 37.7% year-over-year supports improving profitability.
- Price is 6.0% below the 52-week high.
INCY — Competitive Position
Incyte Corporation (INCY) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $25.26B places INCY among large-cap peers.
- Gross margin near 55.7% may reflect pricing power or favorable mix.
INCY — Strengths
Strengths for Incyte Corporation (INCY) inferred from public financial metrics:
- Revenue growth of 37.7% year-over-year.
- Earnings growth of 37.7% year-over-year.
- Return on equity near 30.7% — efficient use of shareholder capital.
- Gross margin of 55.7% supports competitive unit economics.
- Positive free cash flow ($1.18B).
- Moderate leverage (debt/equity 0.60).
INCY — Weaknesses
Weaknesses and pressure points for Incyte Corporation (INCY) based on available data:
Insufficient public data to assess this factor.
INCY — Opportunities
- Sustained revenue growth (37.7%) could support multiple expansion if margins hold.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
INCY — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
INCY — Summary
Incyte Corporation (INCY) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $124.64 with market cap $25.26B. Trailing P/E 16.17×. Revenue grew 37.7% year-over-year per public data. Notable strengths include revenue growth of 37.7% year-over-year. Premium Terminal tools for Incyte Corporation add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open INCY in Vest Terminal
Access live data, filings, ownership, and analysis for Incyte Corporation.
Incyte Corporation FAQ
What does Incyte Corporation (INCY) do?
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refrac…
What is INCY's P/E ratio?
Incyte Corporation has a trailing P/E of 16.17× based on publicly available market data.
Does INCY pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is INCY in?
Incyte Corporation is classified in Healthcare (Biotechnology) on NMS.
What is INCY's market capitalization?
Approximate market cap: $25.26B.
What are the main risks for INCY?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of INCY?
Potential positives include revenue growth of 37.7% year-over-year, earnings growth of 37.7% year-over-year.
Where can I get analyst estimates for INCY?
Public analyst price targets and consensus for Incyte Corporation are on the free /stocks/incy/estimates page. Deeper estimate history and models are available in Vest Terminal.